A detailed history of Black Rock Inc. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,266,714 shares of TARS stock, worth $158 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,266,714
Previous 2,652,680 23.15%
Holding current value
$158 Million
Previous $96.4 Million 7.92%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.17 - $38.73 $15.5 Million - $23.8 Million
614,034 Added 23.15%
3,266,714 $88.8 Million
Q1 2024

May 10, 2024

BUY
$19.61 - $39.22 $2.68 Million - $5.36 Million
136,541 Added 5.43%
2,652,680 $96.4 Million
Q4 2023

Feb 13, 2024

BUY
$12.98 - $20.73 $3.97 Million - $6.34 Million
305,816 Added 13.84%
2,516,139 $51 Million
Q3 2023

Nov 13, 2023

BUY
$14.75 - $24.62 $155,907 - $260,233
10,570 Added 0.48%
2,210,323 $39.3 Million
Q2 2023

Aug 11, 2023

BUY
$11.57 - $19.63 $8.59 Million - $14.6 Million
742,493 Added 50.95%
2,199,753 $39.7 Million
Q1 2023

May 12, 2023

BUY
$11.92 - $16.27 $1.38 Million - $1.89 Million
116,001 Added 8.65%
1,457,260 $18.3 Million
Q4 2022

Feb 13, 2023

BUY
$14.12 - $18.72 $3.14 Million - $4.17 Million
222,498 Added 19.89%
1,341,259 $19.7 Million
Q3 2022

Nov 14, 2022

BUY
$14.08 - $18.5 $1.45 Million - $1.91 Million
103,128 Added 10.15%
1,118,761 $19.2 Million
Q2 2022

Aug 12, 2022

BUY
$11.08 - $19.08 $6.38 Million - $11 Million
575,675 Added 130.85%
1,015,633 $14.8 Million
Q1 2022

May 12, 2022

SELL
$14.49 - $24.28 $130,410 - $218,520
-9,000 Reduced 2.0%
439,958 $7.4 Million
Q4 2021

Feb 10, 2022

BUY
$21.21 - $29.68 $155,638 - $217,791
7,338 Added 1.66%
448,958 $10.1 Million
Q3 2021

Nov 09, 2021

BUY
$21.45 - $29.22 $70,012 - $95,374
3,264 Added 0.74%
441,620 $9.52 Million
Q2 2021

Aug 11, 2021

BUY
$27.16 - $38.59 $11.9 Million - $16.9 Million
438,356 New
438,356 $12.7 Million

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.29B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.